晚期结膜黑色素瘤的遗传特征及全身治疗反应
这项多中心回顾性队列研究纳入34例接受靶向治疗或免疫检查点抑制剂治疗的转移性结膜黑色素瘤患者,其中15例进行了靶向二代测序和RNA测序。遗传分析发现BRAF、NRAS、NF1和TERT启动子突变常见,紫外线相关突变普遍。一线免疫检查点抑制剂和靶向治疗均显示一定疗效。
要点
- 结膜黑色素瘤中BRAF突变占46.7%(7/15),NRAS突变占26.7%(4/15)。
- 一线免疫检查点抑制剂治疗26例,估计1年无进展生存率为42.0%。
- 一线靶向治疗8例,估计1年无进展生存率为54.7%。
核心结论
- 研究结果支持紫外线照射在结膜黑色素瘤中的作用及其与皮肤黑色素瘤的遗传相似性。
- 晚期结膜黑色素瘤患者从靶向治疗(BRAF±MEK抑制剂)和免疫检查点抑制剂中获益。
研究设计与样本
- 多中心回顾性队列研究,并额外筛查ADOREG数据库。
- 共收集34例接受靶向治疗(BRAF±MEK抑制剂)或免疫检查点抑制剂(抗PD-1±抗CTLA4)的转移性结膜黑色素瘤患者数据。
- 其中15例有组织可用于靶向二代测序(611个基因)和RNA测序。
主要发现
- 遗传特征分析发现BRAF突变频率为46.7%(7/15),NRAS为26.7%(4/15),NF1为20%(3/15),TERT启动子为46.7%(7/15)。
- 紫外线相关的C>T和CC>TT突变常见。
- 自首次靶向治疗或免疫检查点抑制剂治疗开始的中位随访时间为13.2个月。
- 26例接受一线免疫检查点抑制剂治疗的患者,估计1年无进展生存率为42.0%,中位无进展生存期为6.2个月,中位总生存期为18.0个月。
- 8例接受一线靶向治疗的患者,估计1年无进展生存率为54.7%,中位无进展生存期为12.6个月,中位总生存期为29.1个月。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Conjunctival melanoma is a rare type of ocular melanoma, which is prone to local recurrence and metastasis and can lead to patient death. Novel therapeutic strategies have revolutionized cutaneous melanoma management. The efficacy of these therapies in conjunctival melanoma, however, has not been evaluated in larger patient cohorts. METHODS: In this multi-center retrospective cohort study with additional screening of the ADOREG database, data were collected from 34 patients with metastatic conjunctival melanoma who received targeted therapy (TT) (BRAF ± MEK inhibitors) or immune checkpoint inhibitors (ICI) (anti-PD-1 ± anti-CTLA4). In 15 cases, tissue was available for targeted next-generation-sequencing (611 genes) and RNA sequencing. Driver mutations, tumor mutational burden, copy number variations and inflammatory/IFNγ gene expression signatures were determined. RESULTS: Genetic characterization identified frequent BRAF (46.7%, 7/15), NRAS (26.7%, 4/15), NF1 (20%, 3/15), and TERT promoter (46.7%, 7/15) mutations. UV associated C>T and CC>TT mutations were common. Median follow-up time after start of first TT or ICI therapy was 13.2 months. In 26 patients receiving first-line ICI, estimated one-year progression-free survival (PFS) rate was 42.0%, PFS and overall survival (OS) 6.2 and 18.0 months, respectively. First-line TT was given to 8 patients, estimated one-year PFS rate was 54.7%, median PFS and OS 12.6 and 29.1 months, respectively. CONCLUSIONS: Our findings support the role of UV irradiation in conjunctival melanoma and the genetic similarity with cutaneous melanoma. Conjunctival melanoma patients with advanced disease benefit from both targeted therapies (BRAF ± MEK inhibitors) and immune checkpoint inhibitors.
引用
- Lodde GC, Jansen P, Möller I, et al. Genetic characterization of advanced conjunctival melanoma and response to systemic treatment. Eur J Cancer. 2022. PMID: 35279471. doi:10.1016/j.ejca.2022.01.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。